Hebei Senlangbio Biotechnology Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
160
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$30.2M
- Investors
-
1
Hebei Senlangbio Biotechnology General Information
Description
Developer of immunotherapy antibody drugs designed to treat malignant tumors. The company's drugs are based on CAR-T/TCR-T, universal CAR-GDT, and CAR-HSPC-NK technology that helps to evaluate the efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of hematopoietic and lymphoid malignancies, enabling patients with relapsed or refractory blood for immune cell therapy including ALL and B-cell Lymphoma.
Contact Information
Website
www.senlangbio.comCorporate Office
- Room 512 and 513, Building 1, 136 Yellow River Avenue
- High-Tech Development Zone
- Shijiazhuang, Hebei 050035
- China
Corporate Office
- Room 512 and 513, Building 1, 136 Yellow River Avenue
- High-Tech Development Zone
- Shijiazhuang, Hebei 050035
- China
Hebei Senlangbio Biotechnology Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Later Stage VC | 18-May-2022 | $30.2M | Completed | Generating Revenue | ||
| 1. Merger/Acquisition | 14-Jun-2021 | Completed | Generating Revenue |
Hebei Senlangbio Biotechnology Patents
Hebei Senlangbio Biotechnology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025190367-A1 | Anti-cldn18.2 nanobody, chimeric antigen receptor, and uses thereof | Pending | 13-Mar-2024 | ||
| EP-4591877-A1 | Novel marrow-infiltrating lymphocytes population comprising chimeric antigen receptor specific for bcma and producing method for the same | Pending | 24-Jan-2024 | ||
| WO-2025159236-A1 | Novel population of marrow-infiltrating lymphocytes comprising bcma-specific chimeric antigen receptor and method for preparing same | Pending | 24-Jan-2024 | ||
| AU-2023418711-A1 | Nanobody targeting bcma, chimeric antigen receptor and use thereof | Pending | 26-Dec-2022 | ||
| EP-4644418-A1 | Nanobody targeting bcma, chimeric antigen receptor and use thereof | Pending | 26-Dec-2022 | C07K16/2878 |
Hebei Senlangbio Biotechnology Signals
Hebei Senlangbio Biotechnology Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Qianhai FoF | Fund of Funds | Minority |
Hebei Senlangbio Biotechnology FAQs
-
When was Hebei Senlangbio Biotechnology founded?
Hebei Senlangbio Biotechnology was founded in 2016.
-
Where is Hebei Senlangbio Biotechnology headquartered?
Hebei Senlangbio Biotechnology is headquartered in Shijiazhuang, China.
-
What is the size of Hebei Senlangbio Biotechnology?
Hebei Senlangbio Biotechnology has 160 total employees.
-
What industry is Hebei Senlangbio Biotechnology in?
Hebei Senlangbio Biotechnology’s primary industry is Drug Discovery.
-
Is Hebei Senlangbio Biotechnology a private or public company?
Hebei Senlangbio Biotechnology is a Private company.
-
What is the current valuation of Hebei Senlangbio Biotechnology?
The current valuation of Hebei Senlangbio Biotechnology is .
-
What is Hebei Senlangbio Biotechnology’s current revenue?
The current revenue for Hebei Senlangbio Biotechnology is .
-
How much funding has Hebei Senlangbio Biotechnology raised over time?
Hebei Senlangbio Biotechnology has raised $30.2M.
-
Who are Hebei Senlangbio Biotechnology’s investors?
Qianhai FoF has invested in Hebei Senlangbio Biotechnology.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process